Skip to search formSkip to main contentSkip to account menu

Dacarbazine

Known as: Dakarbazin, Dacarbazinum, Dacarbazine - DTIC 
A drug that is used to treat Hodgkin lymphoma and malignant melanoma and is being studied in the treatment of other types of cancer. It attaches to… 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2015
Highly Cited
2015
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving… 
Highly Cited
2011
Highly Cited
2011
BACKGROUND Ipilimumab monotherapy (at a dose of 3 mg per kilogram of body weight), as compared with glycoprotein 100, improved… 
Review
2011
Review
2011
BACKGROUND Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more… 
Highly Cited
2002
Highly Cited
2002
Reaction of 1-butyl imidazole with 3-bromopropylamine hydrobromide, followed by workup and anion exchange, yields a new room… 
Highly Cited
2000
Highly Cited
2000
PURPOSE To compare, in 305 patients with advanced metastatic melanoma, temozolomide and dacarbazine (DTIC) in terms of overall… 
Highly Cited
1999
Highly Cited
1999
PURPOSE Several single-institution phase II trials have reported that the Dartmouth regimen (dacarbazine, cisplatin, carmustine… 
Highly Cited
1994
Highly Cited
1994
Production of interleukin-1 and tumour necrosis factor from stimulated human monocytes is inhibited by a new series of pyridinyl… 
Highly Cited
1978
Highly Cited
1978
A human leukemic cell line (designated HL-60) has recently been established from the peripheral blood leukocytes of a patient…